Indication
Treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.
Medicine details
- Medicine name:
- axicabtagene ciloleucel (Yescarta)
- SMC ID:
- SMC2695
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Resubmission
- Publication due date:
- 11 November 2024
- SMC meeting date:
- 01 October 2024
- Patient group submission deadline:
- 06 August 2024